Welcome to our dedicated page for Nanoviricides news (Ticker: NNVC), a resource for investors and traders seeking the latest updates and insights on Nanoviricides stock.
NanoViricides, Inc. (NNVC) generates frequent news as a clinical stage biotechnology company focused on nanomedicine-based antiviral drug candidates. Its updates center on the development and regulatory progress of NV-387, a broad-spectrum antiviral that the company states is designed to mimic host cell attachment receptors such as sulfated proteoglycans, aiming to trap and neutralize a wide range of human pathogenic viruses.
News coverage for NanoViricides often highlights clinical and regulatory milestones. Recent announcements include approval by the regulatory agency ACOREP in the Democratic Republic of Congo to start a Phase II clinical trial of NV-387 for MPox, ongoing work toward a Phase II trial for viral acute and severe acute respiratory infections (viral ARI/SARI), and preparations for orphan drug designation applications for MPox, Smallpox, and Measles. The company also reports on its Phase I safety results for NV-387 and describes its efforts to advance NV-387 into Phase II human clinical trials.
Investors and observers following NNVC news can expect detailed discussions of preclinical and clinical data in animal models and early human studies, including comparisons of NV-387 to existing antivirals such as oseltamivir, baloxavir, peramivir, remdesivir, and tecovirimat. Press releases frequently address emerging viral threats, such as influenza A/H3N2 variants, H5N1 bird flu, MPox clades, coronaviruses, RSV, and Measles, and position NV-387 within these contexts.
NanoViricides also issues news on financing events, such as registered direct offerings and concurrent private placements, which support its research and development plans. Additional coverage includes presentations at investor and partnering conferences, shareholder meeting announcements, and commentary from company leadership on the potential role of nanoviricide technology in pandemic preparedness and bioterrorism response. Bookmark this page to review ongoing NNVC news as the company reports new data, regulatory interactions, and corporate developments.
NanoViricides (NYSE:NNVC) will present at the LSX World Congress in Boston on September 17, 2025, where Dr. Anil R. Diwan will provide updates on the company's drug pipeline and platform technologies. The company's lead candidate, NV-387, is an ultra-broad-spectrum antiviral designed to combat multiple respiratory viruses and is advancing towards Phase II trials for MPOX treatment.
NV-387 has demonstrated effectiveness against the "tripledemic" respiratory viruses (RSV, Influenza A, Coronaviruses) and shown promise in treating Smallpox, MPox, and Measles. The drug's potential market size is estimated at over $10 billion, with additional opportunities through Priority Review Vouchers worth $150-350 million each and possible government contracts for bioterrorism defense.
NanoViricides (NYSE:NNVC) reported that its broad-spectrum antiviral drug NV-387, which has completed Phase I clinical trials, could help reduce metastatic cancer resurgence triggered by viral infections. The drug's unique ability to reduce inflammation, particularly IL-6 cytokine levels, may prevent the reactivation of dormant cancer cells during viral infections.
Research has shown that viral infections like COVID-19 and influenza can reawaken "sleeping" cancer cells, leading to metastasis. NV-387 has demonstrated superior effectiveness compared to existing treatments like Tamiflu, Rapivab, and Xofluza in protecting lungs during lethal viral infections in animal studies. The drug is being advanced to Phase II clinical trials for treating RSV, COVID, Long COVID, Influenza, and other respiratory viral infections.
[ "NV-387 successfully completed Phase I clinical trials", "Drug demonstrates dual action: antiviral effects and inflammation reduction", "Superior lung protection compared to existing approved drugs in animal studies", "Broad-spectrum effectiveness against multiple viruses (RSV, COVID-19, Influenza)", "Potential new application in preventing cancer metastasis during viral infections" ]NanoViricides (NYSE:NNVC) announced that its drug candidate NV-387 could be crucial in fighting the increasing global measles cases. The drug has shown effectiveness against measles in animal studies and completed Phase I trials with no adverse events. NV-387 qualifies for Orphan Drug Designation and may be eligible for Fast Track designation, potentially accelerating its approval process.
The company highlighted concerning measles statistics: 1,319 confirmed cases in the USA, 3,800 cases in Canada, and over 127,350 cases in the European Region in 2024. NV-387 addresses an unmet medical need, as there are currently no approved drugs for measles treatment, while vaccination rates struggle to maintain the required 95% coverage for herd immunity.
NanoViricides (NYSE:NNVC) has detailed the significant market potential of its broad-spectrum antiviral drug NV-387, which has shown effectiveness against multiple viruses including Influenza, Coronaviruses, RSV, MPox, and Measles. The company is advancing toward a Phase II clinical trial for MPox treatment, where NV-387 could become the first approved drug for this indication.
The drug's potential extends to pandemic preparedness, with possible effectiveness against Ebola/Marburg and Hendra/Nipah viruses. The company plans to pursue orphan drug status for several indications and may be eligible for Priority Review Vouchers worth $150-250 million each. NV-387's unique mechanism mimics HSPG, a cell-side molecule that over 90% of human pathogenic viruses bind to, making viral escape unlikely.
NanoViricides (NYSE Amer: NNVC) has achieved a significant breakthrough in developing NV-387, potentially the first-ever drug treatment for Measles. In a humanized animal model study, NV-387 demonstrated strong effectiveness, increasing survival time by 130% (17 days vs. 7.4 days in untreated animals) with no toxicity signs.
The broad-spectrum antiviral drug works by acting as a cell decoy, targeting 90-95% of human pathogenic viruses that require sulfated proteoglycan features. The study utilized specially modified mice bearing the human CD150/SLAM protein, necessary for measles infection. This development is particularly significant as global measles cases rise and vaccination rates decline, especially in industrialized nations.
NanoViricides (NYSE:NNVC) has responded to WHO's extension of the MPox Public Health Emergency status by highlighting the development of their drug candidate NV-387. The company is preparing for Phase II clinical trials of NV-387 for MPox treatment, following successful Phase I safety results where the drug showed no adverse events and demonstrated oral availability.
Unlike current treatments Tecovirimat and Brincidofovir, which have shown limitations and safety concerns, NV-387 employs a unique host-mimetic nanomedicine technology that viruses reportedly cannot escape. The drug achieved a No-Observed-Adverse-Event Level at 1,200 mg/kg in animal studies and is formulated as oral gummies suitable for MPox patients with oral lesions.
The company aims to target a multi-billion-dollar global market for poxvirus bioterrorism preparedness, particularly focusing on the US Strategic National Stockpile market upon successful Phase II trials.
NanoViricides (NYSE:NNVC) has nearly completed the design of an adaptive clinical trial protocol for testing NV-387, their novel broad-spectrum antiviral drug, for treating MPox Virus Clade Ia and Ib infections. The trial will involve approximately 80 patients across two phases (IIa and IIb) in the Democratic Republic of Congo.
The Phase IIa will include 20 patients (10 in treatment arm, 10 in control), while Phase IIb will involve 60 patients in a 2:1 randomization (40 treatment, 20 control). The study will use "NV-387 Oral Gummies," designed specifically for MPox patients who have difficulty swallowing due to mucosal lesions.
If successful, NV-387 would be the first effective drug for MPox treatment in human clinical trials. The company plans to pursue regulatory approvals in Africa, USA, and EU, with potential for Orphan Drug Designation in the USA. The market opportunity is significant, as demonstrated by competitor SIGA's Tecovirimat generating over $600 million in US government sales through December 2024.
NanoViricides (NYSE Amer.:NNVC) has announced plans to advance its lead drug candidate NV-387 into Phase II clinical trials, initially focusing on MPox treatment. The company has already secured a Clinical Trial Site in the Democratic Republic of Congo (DRC) and is finalizing the trial protocol.
The strategic decision to prioritize MPox is driven by several factors: the ongoing epidemic in Africa enabling timely patient recruitment, lower clinical trial costs compared to US/Europe trials, and potential inclusion in the US Strategic National Stockpile (SNS). The company notes that current approved drugs for smallpox treatment, tecovirimat (Tpoxx) and brincidofovir (Tembexa), have shown limitations in MPox treatment.
NanoViricides has developed "NV-387 Oral Gummies" as the drug delivery format, specifically designed for MPox patients who may have difficulty swallowing due to mucosal lesions. The drug substance manufacture is substantially completed at the company's facility, with drug product manufacturing in progress.